60 DEGREES PHARMACEUTICALS, INC.
60 DEGREES PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is B-FREE Chronic Babesiosis Study on February 15, 2027. There are 2 upcoming events on record.
Cash runway is approximately 2.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| February 15, 2027 | B-FREE Chronic Babesiosis Study | Trial Milestone | Phase 2 |
| March 1, 2027 | Oral Tafenoquine Plus Standard of Care Versus Placebo Plus Standard of Care for Babesiosis | Trial Milestone | Phase 2 |
Track SXTP alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open SXTP in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.